ID: MRFR/HC/3661-CR | 85 Pages | Author: Rahul Gotadki | July 2019
1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition 19
3.2 Scope Of The Study 19
3.3 Assumptions & Limitations 19
3.3.1 Assumptions 19
3.3.2 Limitations 19
3.4 Market Structure 19
4 Research Methodology
4.1 Research Process 21
4.1 Primary Research 22
4.2 Secondary Research 23
4.3 Market Size Estimation 24
4.4 Forecast Model 24
5 Market Dynamics
5.1 Introduction 26
5.2 Drivers 27
5.2.1 The Increasing Prevalence Of Epilepsy And Glaucoma 27
5.2.2 Rising Research And Development Funding For Rare Diseases 27
5.2.3 Increasing Focus On Players Towards Sturge-Weber Syndrome 27
5.3 Restraints 28
5.3.1 Side Effects Of Therapeutic Drugs 28
5.4 Opportunities 28
5.4.1 Rising Demand For Laser Therapy 28
5.5 Macroeconomic Indicators 28
6 Market Factor Analysis
6.1 Supply Chain Analysis 30
6.1.1 R&D 30
6.1.2 Parts Manufacturing 30
6.1.3 Distribution 30
6.1.4 Marketing & Sales 30
6.1.5 Post-Sales Monitoring 30
6.2 Demand & Supply: Gap Analysis 31
6.3 Pricing Analysis 31
6.4 Investment Opportunities 31
6.5 Porterβs Five Forces Model 32
6.5.1 Bargaining Power Of Suppliers 33
6.5.2 Bargaining Power Of Buyers 33
6.5.3 Threat Of New Entrants 33
6.5.4 Threat Of Substitutes 33
6.5.5 Intensity Of Rivalry 33
7 Sturge-Weber Syndrome Market, By Type
7.1 Overview 35
7.1.1 Type 1 35
7.1.2 Type 2 35
7.1.3 Type 3 35
8 Sturge-Weber Syndrome Market, By Diagnosis & Treatment
8.1 Overview 39
8.1.1 Treatment 39
8.1.2 Diagnosis 39
9 Sturge-Weber Syndrome Market, By End-User
9.1 Overview 47
9.1.1 Hospital & Clinics 47
9.1.2 Diagnostic Centre 47
10 Sturge-Weber Syndrome Market, By Region
10.1 Introduction 49
10.2 Americas 51
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.2.1 North America 54
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.2.1.1 U.S. 56
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.2.1.2 Canada 58
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.2.2 South America 60
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3 Europe 63
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.1 Western Europe 66
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.1.1 Germany 69
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.1.2 France 71
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.1.3 U.K 73
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.1.4 Italy 75
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.1.5 Spain 77
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.1.6 Rest Of Western Europe 79
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.3.2 Eastern Europe 81
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.4 Asia Pacific 84
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.4.1 Japan 87
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.4.2 China 89
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.4.3 India 91
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.4.4 Australia 93
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.4.5 Republic Of Korea 95
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.4.6 Rest Of Asia Pacific 97
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.5 The Middle East And Africa 99
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.5.1 Middle East 102
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
10.5.2 Africa 104
Sturge-Weber Syndrome Market, By Type
Sturge-Weber Syndrome Market, By Diagnosis & Treatment
Sturge-Weber Syndrome Market, By End-User
11 Competitive Landscape
11.1 Company Market Share Analysis 107
11.1.1 Introduction 107
11.2 Competitive Landscape 108
11.2.1 Introduction 108
11.3 Key Developments 109
12 Company Profiles
12.1 Abbott 111
12.1.1 Company Overview 111
12.1.2 Financial Overview 111
12.1.3 Products Offerings 112
12.1.4 Key Developments 112
12.1.5 SWOT Analysis 112
12.1.6 Key Strategy 112
12.2 Pfizer Inc. 113
12.2.1 Company Overview 113
12.2.2 Financial Overview 113
12.2.3 Products Offerings 114
12.2.4 Key Developments 114
12.2.5 SWOT Analysis 114
12.2.6 Key Strategy 115
12.3 F. Hoffmann-La Roche AG 116
12.3.1 Company Overview 116
12.3.2 Financial Overview 116
12.3.3 Products Offerings 117
12.3.4 Key Developments 117
12.3.5 SWOT Analysis 117
12.3.6 Key Strategy 117
12.4 Novartis AG 118
12.4.1 Company Overview 118
12.4.2 Financial Overview 118
12.4.3 Products Offerings 119
12.4.4 Key Developments 119
12.4.5 SWOT Analysis 119
12.4.6 Key Strategy 119
12.5 UCB S.A. 120
12.5.1 Company Overview 120
12.5.2 Financial Overview 120
12.5.3 Products Offerings 121
12.5.4 Key Developments 121
12.5.5 SWOT Analysis 121
12.5.6 Key Strategy 122
12.6 Sanofi 123
12.6.1 Company Overview 123
12.6.2 Financial Overview 123
12.6.3 Products Offerings 124
12.6.4 Key Developments 124
12.6.5 SWOT Analysis 124
12.6.6 Key Strategy 124
12.7 Shire 125
12.7.1 Company Overview 125
12.7.2 Financial Overview 125
12.7.3 Products Offerings 126
12.7.4 Key Developments 126
12.7.5 SWOT Analysis 127
12.7.6 Key Strategy 127
12.8 Aleva Neurotherapeutics SA 128
12.8.1 Company Overview 128
12.8.2 Products Offering 128
12.8.3 Key Developments 128
12.8.4 SWOT Analysis 128
12.8.5 Key Strategy 128
12.9 GW Pharmaceuticals, Plc. 129
12.9.1 Company Overview 129
12.9.2 Financial Overview 129
12.9.3 Products Offerings 130
12.9.4 Key Developments 130
12.9.5 SWOT Analysis 130
12.9.6 Key Strategy 130
12.10 ElectroCore LLC 131
12.10.1 Company Overview 131
12.10.2 Products Offerings 131
12.10.3 Key Developments 131
12.10.4 SWOT Analysis 131
12.10.5 Key Strategy 131
12.11 Johnson & Johnson 132
12.11.1 Company Overview 132
12.11.2 Financial Overview 132
12.11.3 Products Offerings 133
12.11.4 Key Developments 133
12.11.5 SWOT Analysis 133
12.11.6 Key Strategy 133
13 Appendix
13.1 Discussion Blue Print 135
13.2 References 136
14 List Of Tables
TABLE 1 MARKET SYNOPSIS 17
TABLE 1 PRIMARY INTERVIEWS 22
TABLE 2 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 1, BY REGION 2020β2027 (USD MILLION) 36
TABLE 3 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 2, BY REGION 2020β2027 (USD MILLION) 36
TABLE 4 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 3, BY REGION 2020β2027 (USD MILLION) 37
TABLE 5 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TREATMENT, BY REGION 2020β2027 (USD MILLION) 40
TABLE 6 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSIS, BY REGION 2020β2027 (USD MILLION) 40
TABLE 7 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MEDICATION, BY REGION 2020β2027 (USD MILLION) 40
TABLE 8 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LASER THERAPY, BY REGION 2020β2027 (USD MILLION) 41
TABLE 9 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SURGICAL PROCEDURES, BY REGION 2020β2027 (USD MILLION) 41
TABLE 10 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIEPILEPTIC, BY REGION 2020β2027 (USD MILLION) 41
TABLE 11 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIGLAUCOMA, BY REGION 2020β2027 (USD MILLION) 42
TABLE 12 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LATANOPROST, BY REGION 2020β2027 (USD MILLION) 42
TABLE 13 GLOBAL STURGE-WEBER SYNDROME MARKET FOR BETA-ANTAGONIST EYE DROPS, BY REGION 2020β2027 (USD MILLION) 42
TABLE 14 GLOBAL STURGE-WEBER SYNDROME MARKET FOR CARBONIC ANHYDRASE INHIBITORS, BY REGION 2020β2027 (USD MILLION) 43
TABLE 15 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION 2020β2027 (USD MILLION) 43
TABLE 16 GLOBAL STURGE-WEBER SYNDROME MARKET FOR COMPUTED TOMOGRAPHY (CT) SCAN, BY REGION 2020β2027 (USD MILLION) 43
TABLE 17 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ELECTROENCEPHALOGRAM (EEG), BY REGION 2020β2027 (USD MILLION) 44
TABLE 18 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SKULL RADIOGRAPHY, BY REGION 2020β2027 (USD MILLION) 44
TABLE 19 GLOBAL STURGE-WEBER SYNDROME MARKET FOR HOSPITAL & CLINICS, BY REGION 2020β2027 (USD MILLION) 46
TABLE 20 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSTIC CENTERS, BY REGION 2020β2027 (USD MILLION) 46
TABLE 21 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020β2027 (USD MILLION) 49
TABLE 22 AMERICAS: STURGE-WEBER SYNDROME MARKET, BY REGION, 2020β2027 (USD MILLION) 51
TABLE 23 AMERICAS STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 52
TABLE 24 AMERICAS STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 52
TABLE 25 AMERICAS TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 52
TABLE 26 AMERICAS MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 52
TABLE 27 AMERICAS ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 53
TABLE 28 AMERICAS DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 53
TABLE 29 AMERICAS STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 53
TABLE 30 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020β2027 (USD MILLION) 54
TABLE 31 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 54
TABLE 32 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 54
TABLE 33 NORTH AMERICA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 54
TABLE 34 NORTH AMERICA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 55
TABLE 35 NORTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 55
TABLE 36 NORTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 55
TABLE 37 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 56
TABLE 38 U.S. STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 56
TABLE 39 U.S. STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 56
TABLE 40 U.S. TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 56
TABLE 41 U.S. MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 57
TABLE 42 U.S. ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 57
TABLE 43 U.S. DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 57
TABLE 44 U.S. STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 58
TABLE 45 CANADA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 58
TABLE 46 CANADA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 58
TABLE 47 CANADA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 58
TABLE 48 CANADA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 59
TABLE 49 CANADA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 59
TABLE 50 CANADA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 59
TABLE 51 CANADA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 60
TABLE 52 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 60
TABLE 53 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 60
TABLE 54 SOUTH AMERICA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 60
TABLE 55 SOUTH AMERICA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 61
TABLE 56 SOUTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 61
TABLE 57 SOUTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 61
TABLE 58 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 62
TABLE 59 EUROPE STURGE-WEBER SYNDROME MARKET, BY REGION, 2020β2027 (USD MILLION) 63
TABLE 60 EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 64
TABLE 61 EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 64
TABLE 62 EUROPE TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 64
TABLE 63 EUROPE MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 64
TABLE 64 EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 65
TABLE 65 EUROPE DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 65
TABLE 66 EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 65
TABLE 67 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020β2027 (USD MILLION) 66
TABLE 68 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 66
TABLE 69 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 66
TABLE 70 WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 67
TABLE 71 WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 67
TABLE 72 WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 67
TABLE 73 WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 68
TABLE 74 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 68
TABLE 75 GERMANY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 69
TABLE 76 GERMANY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 69
TABLE 77 GERMANY TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 69
TABLE 78 GERMANY MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 69
TABLE 79 GERMANY ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 70
TABLE 80 GERMANY DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 70
TABLE 81 GERMANY STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 70
TABLE 82 FRANCE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 71
TABLE 83 FRANCE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 71
TABLE 84 FRANCE TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 71
TABLE 85 FRANCE MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 71
TABLE 86 FRANCE ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 72
TABLE 87 FRANCE DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 72
TABLE 88 FRANCE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 72
TABLE 89 U.K. STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 73
TABLE 90 U.K. STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 73
TABLE 91 U.K. TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 73
TABLE 92 U.K. MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 73
TABLE 93 U.K. ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 74
TABLE 94 U.K. DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 74
TABLE 95 U.K. STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 74
TABLE 96 ITALY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 75
TABLE 97 ITALY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 75
TABLE 98 ITALY TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 75
TABLE 99 ITALY MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 75
TABLE 100 ITALY ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 76
TABLE 101 ITALY DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 76
TABLE 102 ITALY STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 76
TABLE 103 SPAIN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 77
TABLE 104 SPAIN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 77
TABLE 105 SPAIN TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 77
TABLE 106 SPAIN MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 77
TABLE 107 SPAIN ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 78
TABLE 108 SPAIN DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 78
TABLE 109 SPAIN STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 78
TABLE 110 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 79
TABLE 111 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 79
TABLE 112 REST OF WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 79
TABLE 113 REST OF WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 80
TABLE 114 REST OF WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 80
TABLE 115 REST OF WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 80
TABLE 116 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 81
TABLE 117 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 81
TABLE 118 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 81
TABLE 119 EASTERN EUROPE TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 81
TABLE 120 EASTERN EUROPE MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 82
TABLE 121 EASTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 82
TABLE 122 EASTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 82
TABLE 123 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 83
TABLE 124 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020β2027 (USD MILLION) 84
TABLE 125 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 85
TABLE 126 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 85
TABLE 127 ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 85
TABLE 128 ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 85
TABLE 129 ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 86
TABLE 130 ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 86
TABLE 131 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 86
TABLE 132 JAPAN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 87
TABLE 133 JAPAN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 87
TABLE 134 JAPAN TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 87
TABLE 135 JAPAN MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 87
TABLE 136 JAPAN ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 88
TABLE 137 JAPAN DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 88
TABLE 138 JAPAN STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 88
TABLE 139 CHINA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 89
TABLE 140 CHINA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 89
TABLE 141 CHINA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 89
TABLE 142 CHINA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 89
TABLE 143 CHINA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 90
TABLE 144 CHINA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 90
TABLE 145 CHINA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 90
TABLE 146 INDIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 91
TABLE 147 INDIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 91
TABLE 148 INDIA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 91
TABLE 149 INDIA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 91
TABLE 150 INDIA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 92
TABLE 151 INDIA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 92
TABLE 152 INDIA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 92
TABLE 153 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 93
TABLE 154 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 93
TABLE 155 AUSTRALIA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 93
TABLE 156 AUSTRALIA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 93
TABLE 157 AUSTRALIA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 94
TABLE 158 AUSTRALIA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 94
TABLE 159 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 94
TABLE 160 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 95
TABLE 161 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 95
TABLE 162 REPUBLIC OF KOREA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 95
TABLE 163 REPUBLIC OF KOREA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 95
TABLE 164 REPUBLIC OF KOREA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 96
TABLE 165 REPUBLIC OF KOREA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 96
TABLE 166 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 96
TABLE 167 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 97
TABLE 168 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 97
TABLE 169 REST OF ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 97
TABLE 170 REST OF ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 97
TABLE 171 REST OF ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 98
TABLE 172 REST OF ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 98
TABLE 173 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 98
TABLE 174 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY REGION, 2020β2027 (USD MILLION) 99
TABLE 175 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 99
TABLE 176 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 100
TABLE 177 MIDDLE EAST AND AFRICA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 100
TABLE 178 MIDDLE EAST AND AFRICA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 100
TABLE 179 MIDDLE EAST AND AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 101
TABLE 180 MIDDLE EAST AND AFRICA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 101
TABLE 181 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 101
TABLE 182 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 102
TABLE 183 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 102
TABLE 184 MIDDLE EAST TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 102
TABLE 185 MIDDLE EAST MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 102
TABLE 186 MIDDLE EAST ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 103
TABLE 187 MIDDLE EAST DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 103
TABLE 188 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 103
TABLE 189 AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020β2027 (USD MILLION) 104
TABLE 190 AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020β2027 (USD MILLION) 104
TABLE 191 AFRICA TREATMENT MARKET, BY TYPE, 2020β2027 (USD MILLION) 104
TABLE 192 AFRICA MEDICATION MARKET, BY TYPE, 2020β2027 (USD MILLION) 104
TABLE 193 AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2020β2027 (USD MILLION) 105
TABLE 194 AFRICA DIAGNOSIS MARKET, BY TYPE, 2020β2027 (USD MILLION) 105
TABLE 195 AFRICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020β2027 (USD MILLION) 105
TABLE 196 GLOBAL STURGE-WEBER SYNDROME MARKET: KEY DEVELOPMENT 109
15 List Of Figures
FIGURE 1 GLOBAL STURGE-WEBER SYNDROME MARKET: MARKET STRUCTURE 19
FIGURE 2 RESEARCH PROCESS OF MRFR 21
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24
FIGURE 4 MARKET DYNAMICS ANALYSIS OF GLOBAL STURGE-WEBER SYNDROME MARKET 26
FIGURE 5 SUPPLY CHAIN: STURGE-WEBER SYNDROME MARKET 30
FIGURE 6 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL STURGE-WEBER SYNDROME MARKET 32
FIGURE 7 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020 (% SHARE) 35
FIGURE 8 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 36
FIGURE 9 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020 (% SHARE) 39
FIGURE 10 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020 & 2027 (USD MILLION) 39
FIGURE 11 GLOBAL STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020 (% SHARE) 47
FIGURE 12 GLOBAL STURGE-WEBER SYNDROME MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 47
FIGURE 13 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020 & 2027 (USD MILLION) 49
FIGURE 14 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020 (% SHARE) 50
FIGURE 15 AMERICAS: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 51
FIGURE 16 EUROPE: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 63
FIGURE 17 ASIA PACIFIC: STURGE-WEBER SYNDROME MARKET SHARE, BY COUNTRY, 2020 (%) 84
FIGURE 18 THE MIDDLE EAST AND AFRICA: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 99
FIGURE 19 GLOBAL STURGE-WEBER SYNDROME MARKET, MARKET SHARE ANALYSIS 2020 (%) 107
FIGURE 20 GLOBAL STURGE-WEBER SYNDROME MARKET: COMPETITIVE LANDSCAPE 2020 (%) 108